Cargando…

Secondary CNS myeloma with remission after systemic CNS-penetrating agents

BACKGROUND: CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Luis G, Oyon, Daniel Eduardo, Gondi, Vinai, Grimm, Sean, Khan, Osaama H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307102/
https://www.ncbi.nlm.nih.gov/pubmed/35892045
http://dx.doi.org/10.1093/noajnl/vdac106
_version_ 1784752688500572160
author Fernandez, Luis G
Oyon, Daniel Eduardo
Gondi, Vinai
Grimm, Sean
Khan, Osaama H
author_facet Fernandez, Luis G
Oyon, Daniel Eduardo
Gondi, Vinai
Grimm, Sean
Khan, Osaama H
author_sort Fernandez, Luis G
collection PubMed
description BACKGROUND: CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radiotherapy regimens have been described. METHODS: We had previously reported on the efficacy of proton-based craniospinal irradiation in a patient with CNS myeloma; here we present a patient with a history of extramedullary plasmacytoma, 10 years in remission status post standard systemic chemotherapy, with biopsy-proven CNS myeloma successfully treated with systemic chemotherapy as a first-line treatment. RESULTS: The patient achieved clinical and radiographic remission on 2 separate occasions with systemic chemotherapy alone. CONCLUSIONS: This case demonstrates that systemically administered agents may have activity in CNS myeloma. Further investigations are necessary to establish the optimal combination of agents and treatment schedules.
format Online
Article
Text
id pubmed-9307102
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93071022022-07-25 Secondary CNS myeloma with remission after systemic CNS-penetrating agents Fernandez, Luis G Oyon, Daniel Eduardo Gondi, Vinai Grimm, Sean Khan, Osaama H Neurooncol Adv Clinical Investigations BACKGROUND: CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radiotherapy regimens have been described. METHODS: We had previously reported on the efficacy of proton-based craniospinal irradiation in a patient with CNS myeloma; here we present a patient with a history of extramedullary plasmacytoma, 10 years in remission status post standard systemic chemotherapy, with biopsy-proven CNS myeloma successfully treated with systemic chemotherapy as a first-line treatment. RESULTS: The patient achieved clinical and radiographic remission on 2 separate occasions with systemic chemotherapy alone. CONCLUSIONS: This case demonstrates that systemically administered agents may have activity in CNS myeloma. Further investigations are necessary to establish the optimal combination of agents and treatment schedules. Oxford University Press 2022-07-01 /pmc/articles/PMC9307102/ /pubmed/35892045 http://dx.doi.org/10.1093/noajnl/vdac106 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Investigations
Fernandez, Luis G
Oyon, Daniel Eduardo
Gondi, Vinai
Grimm, Sean
Khan, Osaama H
Secondary CNS myeloma with remission after systemic CNS-penetrating agents
title Secondary CNS myeloma with remission after systemic CNS-penetrating agents
title_full Secondary CNS myeloma with remission after systemic CNS-penetrating agents
title_fullStr Secondary CNS myeloma with remission after systemic CNS-penetrating agents
title_full_unstemmed Secondary CNS myeloma with remission after systemic CNS-penetrating agents
title_short Secondary CNS myeloma with remission after systemic CNS-penetrating agents
title_sort secondary cns myeloma with remission after systemic cns-penetrating agents
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307102/
https://www.ncbi.nlm.nih.gov/pubmed/35892045
http://dx.doi.org/10.1093/noajnl/vdac106
work_keys_str_mv AT fernandezluisg secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents
AT oyondanieleduardo secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents
AT gondivinai secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents
AT grimmsean secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents
AT khanosaamah secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents